Novel Genomic Test Helps Improve Diagnosis of Idiopathic Pulmonary Fibrosis SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 22, 2019-- Veracyte, Inc . (Nasdaq: VCYT), a leading genomic diagnostics company, announced today that it has received regulatory authorization from the New York State
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 22, 2019-- Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, today announced that it has named Alfred “Freddie” Bowie, Jr., Ph.D., as vice president, corporate and business development. In this role, Dr.
RNA whole-transcriptome and machine learning platform enables genomic test to distinguish benign Hürthle cells, reducing potential for unnecessary surgeries SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 8, 2019-- Veracyte, Inc . announced today that a new study published online in BMC Systems
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 3, 2019-- Veracyte, Inc. (Nasdaq: VCYT) today announced that it will release its financial results for the first quarter 2019 after the close of market on Tuesday, April 30, 2019 . Company management will host a conference call and webcast to
Novel genomic test distinguishes IPF from other lung-scarring diseases without the need for surgery SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 1, 2019-- Veracyte, Inc . announced that data published online today in The Lancet Respiratory Medicine suggest that use of the company’s Envisia
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 28, 2019-- Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, today announced that Bonnie H. Anderson , chairman and chief executive officer, is scheduled to present at the 18 th Annual Needham Healthcare Conference in New York
Findings Presented at ENDO 2019 Conference SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 25, 2019-- Veracyte, Inc . (Nasdaq: VCYT) announced today that new data from the Afirma® Xpression Atlas suggest that the majority of newly diagnosed medullary thyroid cancers (MTC) are associated with
Support Reinforces Company’s Commitment to Tackling This Deadly Disease SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 19, 2019-- Veracyte, Inc. (Nasdaq: VCYT), a leading genomics diagnostics company, today announced its “Summit” level sponsorship of the Climb to Fight Cancer’s Team
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 18, 2019-- Veracyte, Inc. (Nasdaq: VCYT) announced today that new data derived from the Afirma® Xpression Atlas, which help characterize the genomic underpinning of medullary thyroid cancer (MTC), will be presented at ENDO 2019, the Endocrine
Genomic Test is the First to Be Granted Medicare Coverage for Improved Diagnosis of Idiopathic Pulmonary Fibrosis (IPF) SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 4, 2019-- Veracyte, Inc. (Nasdaq: VCYT) announced today that it has received a final Medicare local coverage determination
The information in our press releases and webcasts should be considered accurate only as of the date of the press release or presentation. We disclaim any obligation to supplement or update the information in these press releases or presentations.
